Roche ’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome

Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of RoActemra ® (tocilizumab) for the treatment of cytokine release syndrome (CRS), in adults and pediatric patients aged two years and older.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news